A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer

Purpose: Platinum resistance in ovarian cancer (OC) is associated with epigenetic modifications. Hypomethylating agents (HMAs) have been studied as carboplatin re-sensitizing agents in OC. This randomized phase 2 trial compared guadecitabine, a second generation HMA, and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable platinum-resistant OC. Experimental…

Read the full article here

Source: Clinical Cancer Research

Categories: Hem/Onc News and Journals

Tweets with this article

NatureRevClinOncol

in phase II trial, epigenetic priming with guadecitabine versus placebo was added to chemotherapy of patients with ovarian cancer but PFS end point not met https://t.co/IUecY4d64v i

Related Articles

Tumour and microenvironment crosstalk in NSCLC progression and response to therapy

Nature Reviews Clinical Oncology – Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of…

NatureRevClinOncol May 16, 2025

Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention

Nature Reviews Clinical Oncology – The composition of the gut microbiota has been implicated as a key determinant of not only the clinical efficacy but…

NatureRevClinOncol May 14, 2025

Targeting the glioblastoma resection margin with locoregional nanotechnologies

Nature Reviews Clinical Oncology – Patients with resectable glioblastoma undergo upfront surgery followed by adjuvant radiotherapy plus chemotherapy. This approach implies a period of approximately…

NatureRevClinOncol May 14, 2025

Promising results with zongertinib in advanced-stage HER2-mutant NSCLC

Nature Reviews Clinical Oncology – Promising results with zongertinib in advanced-stage HER2-mutant NSCLC

NatureRevClinOncol May 13, 2025

Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer

Nature Reviews Clinical Oncology – Anal squamous cell carcinoma (ASCC) is a rare malignancy, albeit with an increasing prevalence in most economically developed countries. Despite…

NatureRevClinOncol May 13, 2025

Next-generation KRAS-G12C inhibitor D3S-001 shows promise

Nature Reviews Clinical Oncology – Next-generation KRAS-G12C inhibitor D3S-001 shows promise

NatureRevClinOncol May 9, 2025

Improving outcomes of patients with pancreatic cancer

Nature Reviews Clinical Oncology – The incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing over the past few decades and survival rates for patients…

NatureRevClinOncol May 8, 2025

Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours

Nature Reviews Clinical Oncology – Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours

NatureRevClinOncol May 7, 2025

Improving outcomes of patients with pancreatic cancer

Nature Reviews Clinical Oncology – The incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing over the past few decades and survival rates for patients…

NatureRevClinOncol May 6, 2025

Improving outcomes of patients with pancreatic cancer

Nature Reviews Clinical Oncology – The incidence of pancreatic ductal adenocarcinoma (PDAC) has been increasing over the past few decades and survival rates for patients…

NatureRevClinOncol May 6, 2025